Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

• Status: Terminated
• Trial end date: 2020-10-07
• Target enrollment: 0
• Participant gender: All

Summary

Aim 1. To determine the effect of Allopurinol treatment on renal function (glomerular filtration rate, GFR) in pediatric chronic kidney disease (CKD) patients with high uric acid levels (hyperuricemia).

Aim 2. Establish whether Allopurinol treatment reduces Nlrp3 inflammasome and renal injury biomarkers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Allopurinol; Uric Acid

Criteria

Inclusion Criteria:

• Chronic Kidney Disease stage 1-5

• Hyperuricemic (UA >= 5.5 mg/dL)

Exclusion Criteria:

• Contraindication to Allopurinol

• Elevated baseline liver function tests

• Receiving acute or chronic dialysis

• Primary metabolic disorder

• Sickle cell disease

• Autosomal Dominant Polycystic Kidney Disease

• Cystinosis

• Bartter or Gitelman Disease

• Pregnant or nursing